 Bullous pemphigoid is the most common autoimmune blistering disease of the skin, usually affecting the elderly. It is a chronic disease characterized by spontaneous exacerbations and remissions. Bullous pemphigoid is mediated by IgG autoantibodies directed against hemidesmosomal proteins BP180, BP230, which are involved in dermal-epidermal adhesion in the skin. The diagnosis of bullous pemphigoid is based on clinical and immunopathological findings, including skin direct immunofluorescence. The disease usually requires on average a 1-year duration of treatment although a long-term maintenance therapy may be necessary some cases. High doses oral corticosteroids have been considered as the mainstay of treatment for many years, but are deleterious, with a high rate of treatment side effects, including mortality. Topical superpotent corticosteroids have been demonstrated to be as effective but safer than high doses of oral corticosteroids, reducing side effects and mortality rate, while controlling the disease in between 95 to 100 of cases. Despite its high efficacy, topical superpotent corticosteroid therapy is often considered as poorly convenient. In addition, immunosuppressant drugs and methotrexate are poorly tolerated or frequently contra-indicated in those elderly patients with bullous pemphigoid. To date, no study has evaluated the real-world use and costs of the different treatments in this disease. 